Clinical Investigator & Sponsor
Roles & Responsibilities for Devices

Nichole Chamberlain, MSN, FNP
Senior Regulatory Officer, FDA/CDRH
Agenda

• **Bioresearch Monitoring (BIMO) Program**
• Drug vs Device Studies
• Definitions
• Clinical Investigator & Sponsor Responsibilities
• Common Deficiencies
BIMO Program

- FDA-wide program
- Site inspections and data audits
- Oversees FDA-regulated research
  - Significant Risk Devices
  - Non-Significant Risk Devices
  - Exempt Devices

Clinical Investigator Training Course 11.14.13
BIMO Program Objectives

• Protect the rights, safety and welfare of subjects in FDA-regulated trials.

• Determine the accuracy and reliability of clinical trial data submitted to FDA in support of research or marketing applications.

• Assess compliance with FDA’s regulations governing the conduct of clinical trials, including those for informed consent and ethical review.
BIMO Program Inspection Types

- Sponsors/Monitors/CRO’s
- Institutional Review Boards
- Clinical Investigators
- Non-Clinical Laboratories
FDA Regulations for Devices

21 CFR…

• Part 50: Human Subject Protections
• Part 54: Financial Disclosure
• Part 56: Institutional Review Boards
• Part 809: In Vitro Diagnostic Products (IVD)
• Part 812: Investigational Device Exemption (IDE)
• Part 814: Premarket Approval (PMA)
Agenda

• Bioresearch Monitoring (BIMO) Program
• Drug vs Device Studies
• Definitions
• Regulatory Responsibilities
• Common Deficiencies
# Drug vs Devices

<table>
<thead>
<tr>
<th></th>
<th>Drugs</th>
<th>Devices</th>
</tr>
</thead>
<tbody>
<tr>
<td># of subjects</td>
<td>1000’s</td>
<td>100’s</td>
</tr>
<tr>
<td>Trial Design</td>
<td>Phase I, II, III, IV</td>
<td>Feasibility, Pivotal</td>
</tr>
<tr>
<td>Blinding</td>
<td>Common</td>
<td>Difficult</td>
</tr>
<tr>
<td>CI Training</td>
<td>Important</td>
<td>Critical</td>
</tr>
</tbody>
</table>

Clinical Investigator Training Course 11.14.13
Drug vs Devices
Adverse Events

**Devices**: investigators shall submit to the sponsor and reviewing IRB a report of any unanticipated adverse device effect occurring during an investigation. 21 CFR 812.150(a)(1)

**Drugs**: investigators shall promptly report to the sponsor any adverse effect that may reasonably be regarded as caused by, or probably caused by, the drug. 21 CFR 312.64(b)
Drug vs Devices

Adverse Events

**Devices**: sponsors shall report results of an evaluation of an unanticipated adverse device effect to FDA and all reviewing IRBs within 10 working days. 21 CFR 812.150(b)(1)

**Drugs**: sponsors shall notify FDA of any unexpected fatal or life-threatening event within 7 calendar days (IND Safety Report) 21 CFR 312.32
Drug vs Devices
Contract Research Organizations (CROs)

Device regulations
- DO NOT transfer responsibilities to CROs
- Sponsor is ultimately held responsible

Drug regulations
- Define transfer of responsibilities to CROs
- CROs are held responsible
Agenda

- Bioresearch Monitoring (BIMO) Program
- Drug vs Device Studies
- Definitions
- Regulatory Responsibilities
- Common Deficiencies
Significant Risk Studies
21 CFR 812.3(m)

FDA approved – IDE required
• Intended as implant
• Support/sustain human life
• Substantial importance in diagnosing, curing, mitigating, treating disease or preventing impairment of human health

• Potential of serious risk to health, safety or welfare of subject

*Uncertain in risk classification - call FDA
Non-Significant Risk Studies
21 CFR 812.2(b)

• Do not meet Significant Risk definition
• Based on indication, not just device
• Sponsor responsibilities:
  – No FDA approved required
  – IRB determines NSR vs SR
  – Comply with labeling
  – Informed consent
  – Monitor
  – Selected records and reports
  – Comply with investigational promotion & advertising
Sponsor
21 CFR 812.3(n)

Person, i.e., individual, company, gov’t agency, academic institution, private organization, who

• Takes responsibility

• Initiates investigation
Clinical Investigator
21 CFR 812.3(i)

- an individual or responsible leader
- actually conducts a clinical investigation
- immediate direction
- test article administer, dispense, or use
- a research subject
Sponsor-Investigator

21 CFR 812.3(o)

• Individual, alone or with others
• initiates & actually conducts
• immediate direction
• test article
• administer, dispense, or use
• a research subject
Unanticipated Adverse Device Effect

21 CFR 812.3(s)

Any serious adverse effect on the health or safety of a subject or any life-threatening problem or death caused by or associated with the device that was not previously identified in nature, severity, or degree of incidence in the investigational plan, or any other unanticipated serious problem associated with a device
Agenda

- Bioresearch Monitoring (BIMO) Program
- Drug vs Device Studies
- Definitions
- Regulatory Responsibilities
- Common Deficiencies
Sponsor Responsibilities
21 CFR 812 Subparts C & G

• General Duties
• Selection of Investigators
• Monitoring
• Controlling Distribution and Disposition of Devices

• Prohibition of Promotion and Other Practices
• Supplemental Applications
• Maintaining Records
• Submitting Reports
• Inspections
Investigator Responsibilities
21 CFR 812 Subparts E & G

- General Responsibilities
- Specific Responsibilities
- Maintaining Records
- Inspections
- Submitting Reports
- Device Distribution and Tracking
- Prohibition of Promotion and Other Practices
- Annual Progress Reports and Final Reports
Sponsor-Investigator Responsibilities

All of the above
Clinical Investigator Responsibilities

21 CFR 812. 100 – General Responsibilities

• Protocol Adherence

• FDA Regulations

• Subject Rights, Safety & Welfare

• Device Control
Clinical Investigator Responsibilities

21 CFR 812. 110 – Specific

- IRB approval
  - Required prior to subject participation
  - Required prior to enrolling subjects
  - Required prior to consenting subjects

- Compliance
  - FDA regulations
  - Sponsor agreement
  - Protocol

- Device Use
  - Only used for subjects in the study
  - Only used by authorized study personnel

- Financial Disclosure
Clinical Investigator Responsibilities

Records & Reports

21 CFR 812.140(a)

- All correspondence
- Device Tracking (receipt, use, disposition)
- Subject Records
- Protocol Deviations
- Any other records required by regulation
Clinical Investigator Responsibilities
Reports to the Sponsor & IRB
Reports 21 CFR 812.150

• Unanticipated Adverse Device Effects (10 days)
• IRB approval withdrawal (5 days-sponsor only)
• Progress (yearly – monitor too)
• Deviations - emergencies (5 days)
• Device use w/o Informed Consent (5 days)
• Final Report (3 months)
Record Retention
21 CFR 812.140(d)

• Throughout the study
• 2 years after
  – Termination/completion of study; or
  – No longer needed to support PMA
* whichever is latest
• Transfer custody
  – notify FDA in 10 working days after transfer
  – New custodian must comply w/retention requirements
Agenda

• Bioresearch Monitoring (BIMO) Program
• Drug vs Device Studies
• Definitions
• Clinical Investigator & Sponsor Responsibilities
• **Common Deficiencies**
Common Investigator Deficiencies

- Did not follow investigational plan or FDA regs
- Did not follow signed investigator agreement
- Inadequate case history/device exposure
- Improper informed consenting
- Inadequate records
  - protocol/deviations
  - adverse effects
  - relevant observations
  - device accountability
Considerations

• Principle Investigator is ultimately responsible
  – Not delegates
  – Not study staff
  – Not clinical coordinator

• Imperative to obtain and review hospital records during course of study

• Report findings as per protocol & regulation
Common Sponsor Deficiencies

- Inadequate monitoring
- Record keeping
- Failure to report UADEs
- Inadequate device accountability
- Failure to obtain FDA/IRB approval
Considerations

• Select qualified study staff
• Identify and select appropriate sites
• Obtain feedback on protocol requirements
• Provide adequate training up front
  – Stress informed consent process requirements
  – Stress protocol adherence requirements
• Ensure adequate monitoring
• Bring investigators into compliance
Resources

Significant Risk vs Non-Significant Risk Devices

Bioresearch Monitoring Internet
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/BioresearchMonitoring/default.htm

Bioresearch Monitoring Learning Modules
http://www.fda.gov/Training/CDRHLearn/ucm162015.htm

Sponsor responsibilities for significant risk devices
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/InvestigationalDeviceExemptionIDE/ucm049859.htm

Investigator responsibilities for significant risk devices
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/InvestigationalDeviceExemptionIDE/ucm049864.htm
Questions?
Contact Information

• Nichole Chamberlain
• Senior Regulatory Officer
• WO 66, Room 3568
• Phone: 301-796-5667
• E-mail: nichole.chamberlain@fda.hhs.gov